Trial Profile
A Randomized, Double-blinded, Placebo-controlled, Dose-escalation Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant HIV Envelope Protein BG505 SOSIP.664 gp140 Vaccine, Adjuvanted, in Healthy, HIV-1 Uninfected Adults
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 20 Dec 2023
Price :
$35
*
At a glance
- Drugs BG505 SOSIP 664 gp140 adjuvanted vaccine (Primary)
- Indications HIV infections
- Focus Adverse reactions; First in man
- 13 Dec 2023 Status changed from active, no longer recruiting to completed.
- 06 May 2022 Planned End Date changed from 20 May 2020 to 30 Aug 2023.
- 06 May 2022 Planned primary completion date changed from 20 May 2020 to 30 Mar 2023.